Virtuoso Therapeutics to Present Preclinical Findings on Three Best-in-Class Bispecific and ADC Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

On April 11, 2023 Virtuoso Therapeutics, Inc., a private oncology-focused company developing novel bispecific antibodies reported that it will present three posters highlighting the preclinical data from leading bispecific antibody and ADC programs at the American Associate for Cancer Research (AACR) (Free AACR Whitepaper) 2023 Annual Meeting (Press release, Virtuoso Therapeutics, APR 11, 2023, View Source [SID1234629966]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the Company’s presentations at the AACR (Free AACR Whitepaper) are as follows:

Poster Presentation #1870:

Title: VBI–003, a CD47xEpCAM bispecific antibody as a potential treatment for colorectal and small cell lung cancers
Session Category: Immunology
Session Title: Therapeutic Antibodies 1
Presenting Author: Oi Kwan Wong, Ph.D., Senior Director, Translational Biology
Date/Time: April 17th 9:00AM-12:30PM
Location: Section 25

Poster Presentation #6334:

Title: VBI-002, a CD47xICAM-1 bispecific antibody for the treatment of hepatocellular carcinoma, melanoma and non-small cell lung cancers
Session Category: Immunology
Session Title: Anticancer Immunotherapeutics
Presenting Author: Oi Kwan Wong, Ph.D., Senior Director, Translational Biology
Date/Time: April 19th 9:00AM-12:30PM
Location: Section 22

Poster Presentation #6298:

Title: A novel topoisomerase I inhibitor based anti-ICAM–1 antibody drug conjugate for the treatment of hematologic malignancies and solid tumors
Session Category: Experimental and Molecular Therapeutics
Session Title: Growth Factor Receptors as Therapeutic Targets
Presenting Author: Oi Kwan Wong, Ph.D., Senior Director, Translational Biology
Date/Time: April 19th 9:00AM-12:30PM
Location: Section 21

"We believe that our best-in-class CD47 bispecific antibodies confer greater tumor selectivity without sacrificing potency and efficacy. They have been optimized and are ready to begin IND enabling studies," said Sofie Qiao, PhD, President and CEO of Virtuoso Therapeutics. Posters will be available at www.virtuosotherapuetics.com after the meeting.